Jane Delima Thomas, MD - Medicare Hospice/palliative Care in Boston, MA

Jane Delima Thomas, MD is a medicare enrolled "Internal Medicine - Hospice And Palliative Medicine" physician in Boston, Massachusetts. She went to University Of Massachusetts Medical School and graduated in 2000 and has 24 years of diverse experience with area of expertise as Hospice/palliative Care. She is a member of the group practice Dana-farber Cancer Institute, Inc. and her current practice location is 450 Brookline Ave, Boston, Massachusetts. You can reach out to her office (for appointments etc.) via phone at (617) 632-6464.

Jane Delima Thomas is licensed to practice in Massachusetts (license number 224093) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1649218918.

Contact Information

Jane Delima Thomas, MD
450 Brookline Ave,
Boston, MA 02215-5418
(617) 632-6464
(617) 632-6180



Physician's Profile

Full NameJane Delima Thomas
GenderFemale
SpecialityHospice/palliative Care
Experience24 Years
Location450 Brookline Ave, Boston, Massachusetts
Accepts Medicare AssignmentsYes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Jane Delima Thomas attended and graduated from University Of Massachusetts Medical School in 2000
  NPI Data:
  • NPI Number: 1649218918
  • Provider Enumeration Date: 06/02/2006
  • Last Update Date: 05/08/2019
  Medicare PECOS Information:
  • PECOS PAC ID: 7517958317
  • Enrollment ID: I20050711000139

Medical Identifiers

Medical identifiers for Jane Delima Thomas such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1649218918NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
207RG0300XInternal Medicine - Geriatric Medicine 224093 (Massachusetts)Secondary
207RH0002XInternal Medicine - Hospice And Palliative Medicine 224093 (Massachusetts)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Brigham And Women's HospitalBoston, MAHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Dana-farber Cancer Institute, Inc.9133038904538

News Archive

Researchers unravel how nature releases the torque built up in DNA at the molecular level

A Dutch led international team of researchers has unravelled how nature releases the torque built up in DNA at the molecular level. The researchers from Delft University of Technology, the Ecole Normale Supérieure in Paris and the Sloan-Kettering Institute in New York published their findings in the 31 March 2005 issue of Nature. An artistic impression of the enzyme at work is featured on the cover of this issue.

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

Allergy season comes early with high pollen counts

After the end of an unusually warm winter the spring has come early and this has affected asthmatics in parts of the South and Midwest this year. The 25 to 35 percent of people who suffer from hay fever, the early arrival of warm weather meant an unusually early start to allergy season due to the abundance of pollens.

Read more Medical News

› Verified 2 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Jane Delima Thomas allows following entities to bill medicare on her behalf.
Entity NameDana-farber Cancer Institute, Inc.
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1346433257
PECOS PAC ID: 9133038904
Enrollment ID: O20040223000142

News Archive

Researchers unravel how nature releases the torque built up in DNA at the molecular level

A Dutch led international team of researchers has unravelled how nature releases the torque built up in DNA at the molecular level. The researchers from Delft University of Technology, the Ecole Normale Supérieure in Paris and the Sloan-Kettering Institute in New York published their findings in the 31 March 2005 issue of Nature. An artistic impression of the enzyme at work is featured on the cover of this issue.

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

Allergy season comes early with high pollen counts

After the end of an unusually warm winter the spring has come early and this has affected asthmatics in parts of the South and Midwest this year. The 25 to 35 percent of people who suffer from hay fever, the early arrival of warm weather meant an unusually early start to allergy season due to the abundance of pollens.

Read more Medical News

› Verified 2 days ago

Entity NameDana-farber Cancer Institute, Inc.
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1851333686
PECOS PAC ID: 9133038904
Enrollment ID: O20040223000228

News Archive

Researchers unravel how nature releases the torque built up in DNA at the molecular level

A Dutch led international team of researchers has unravelled how nature releases the torque built up in DNA at the molecular level. The researchers from Delft University of Technology, the Ecole Normale Supérieure in Paris and the Sloan-Kettering Institute in New York published their findings in the 31 March 2005 issue of Nature. An artistic impression of the enzyme at work is featured on the cover of this issue.

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

Allergy season comes early with high pollen counts

After the end of an unusually warm winter the spring has come early and this has affected asthmatics in parts of the South and Midwest this year. The 25 to 35 percent of people who suffer from hay fever, the early arrival of warm weather meant an unusually early start to allergy season due to the abundance of pollens.

Read more Medical News

› Verified 2 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jane Delima Thomas is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Jane Delima Thomas, MD
24 Southbourne Rd,
Jamaica Plain, MA 02130-4633

Ph: (617) 632-6464
Jane Delima Thomas, MD
450 Brookline Ave,
Boston, MA 02215-5418

Ph: (617) 632-6464

News Archive

Researchers unravel how nature releases the torque built up in DNA at the molecular level

A Dutch led international team of researchers has unravelled how nature releases the torque built up in DNA at the molecular level. The researchers from Delft University of Technology, the Ecole Normale Supérieure in Paris and the Sloan-Kettering Institute in New York published their findings in the 31 March 2005 issue of Nature. An artistic impression of the enzyme at work is featured on the cover of this issue.

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

Allergy season comes early with high pollen counts

After the end of an unusually warm winter the spring has come early and this has affected asthmatics in parts of the South and Midwest this year. The 25 to 35 percent of people who suffer from hay fever, the early arrival of warm weather meant an unusually early start to allergy season due to the abundance of pollens.

Read more News

› Verified 2 days ago


Internal Medicine Doctors in Boston, MA

Kaitlyn My-tu Lam, MBBS
Internal Medicine
Medicare: Not Enrolled in Medicare
Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114
Phone: 617-724-7738    
Kui Toh Gerard Leong, M.D.
Internal Medicine
Medicare: Not Enrolled in Medicare
Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114
Phone: 617-726-8862    
Ruma Rajbhandari,
Internal Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 75 Francis St, Boston, MA 02115
Phone: 617-525-6841    
Alaka Ray, M.D.
Internal Medicine
Medicare: Accepting Medicare Assignments
Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114
Phone: 617-726-2066    
Meghan E Sise, M.D.
Internal Medicine
Medicare: Accepting Medicare Assignments
Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114
Phone: 617-726-2862    
Aaron Dickstein, M.D.
Internal Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 800 Washington St, Box 233, Boston, MA 02111
Phone: 617-636-5883    Fax: 617-636-9292
Dr. Felicia Elizabeth Patch, MD
Internal Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118
Phone: 617-414-4376    Fax: 617-414-4676

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.